TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna’s mRNA flu vaccine, mFlusiva, has launched in limited quantities after FDA approval in August 2026 for adults 50 and older. The company says it is available at more than 13,000 locations; people may need to use its vaccine finder or call pharmacies to check stock. Evidence comparing its clinical protection with enhanced flu vaccines remains limited.
Moderna’s mRNA flu vaccine, mFlusiva, is available at more than 13,000 locations for the 2026-27 season, but the company and infectious-disease experts say supplies are limited after the shot’s FDA approval in August. Adults ages 50 and older who want it may need to check Moderna’s vaccine finder or call pharmacies, rather than assume their usual pharmacy has it.
Moderna told MedPage Today it planned a “limited launch in year one.” A company spokesperson said the vaccine is offered at more than 13,000 locations and provided the publication with a link to the company’s vaccine finder. The report did not identify specific pharmacy chains or provide a location-by-location inventory, so availability should be checked directly before making a trip.
Amesh Adalja, a physician at the Johns Hopkins Center for Health Security, told MedPage Today that late approval contributed to limited supply: national retail pharmacy chains had already ordered this season’s flu vaccines before mFlusiva was approved. He advised people seeking the shot to use the finder or call around. The vaccine is approved for adults 50 and older; the FDA granted traditional approval for ages 50 to 64 and accelerated approval for those 65 and older, with a postmarketing effectiveness study planned for the older group.
The choice is not limited to mFlusiva. U.S. flu vaccines also include standard-dose shots, a nasal spray, and enhanced vaccines such as Flublok, Flucelvax, Fluzone High-Dose and Fluad. The products differ in how they are made and in their formulations. MedPage Today reports that all U.S. flu vaccines are now trivalent, covering three influenza virus strains.
Finding the Shot During Flu Season
Limited availability matters for people who specifically want an mRNA vaccine, but it does not mean they need to delay vaccination while searching for it. William Schaffner of Vanderbilt University, an Infectious Diseases Society of America spokesperson, told MedPage Today that people who have not been vaccinated should get an available flu vaccine. He said influenza had started early in many parts of the country.
The practical decision involves both access and preference. Adalja said people should weigh any possible added protection against the shot’s more frequent short-term reactions. The report cites trial data showing higher rates of injection-site pain, fatigue, headache and muscle aches than with standard-dose shots. The available information does not establish that mFlusiva provides better clinical protection than enhanced vaccines.
As an affiliate, we earn on qualifying purchases.
Approval Came After Pharmacy Orders
Moderna’s vaccine entered the season after retail pharmacy chains had placed orders for flu vaccines, according to Adalja’s account to MedPage Today. That timing, along with uncertainty about demand, helps explain why the company described its initial rollout as limited. The report does not say that every listed location has doses in stock.
The FDA’s approval followed a dispute over the evidence supporting the application. MedPage Today reported that the agency initially declined to review it over concerns about the study comparator, then reversed course a week later. The pivotal phase III study compared mFlusiva with a standard-dose vaccine. A separate phase III study found a stronger immune response than Fluzone High-Dose among adults 65 and older, but it did not measure clinical outcomes such as whether participants were less likely to get influenza.
Under the FDA’s decision, approval for people 65 and older is accelerated and comes with a required postmarketing effectiveness study. The report says an enhanced vaccine would be an ideal comparator for that study. This distinction matters: immune-response findings are not, by themselves, proof of better protection in real-world use.
“If someone wants to get mFlusiva, they’re going to have to use that website or call around.”
— Amesh Adalja, Johns Hopkins Center for Health Security, speaking to MedPage Today
As an affiliate, we earn on qualifying purchases.
Protection Compared With Enhanced Shots
It remains unclear whether mFlusiva provides better clinical protection than enhanced flu vaccines. The pivotal trial compared it with a standard-dose vaccine, and the separate study in adults 65 and older measured immune response rather than clinical outcomes. The FDA’s postmarketing study for the older age group is intended to address effectiveness, but the report does not give a completion date or results.
Local stock is also uncertain. Moderna’s figure of more than 13,000 locations does not establish that each location currently has doses available. The report gives no inventory count, regional breakdown or estimate of how quickly supplies may run out. People should confirm availability with a pharmacy before traveling.
Schaffner also said mRNA technology could potentially allow vaccines to be matched more closely to circulating strains, but described that as a possibility and said changes would require policy work by the FDA and potentially the World Health Organization. It is not a confirmed change to vaccine selection for this season.
As an affiliate, we earn on qualifying purchases.
Check Stock and Watch Study Results
People seeking mFlusiva can use Moderna’s vaccine finder, as linked by the company in its statement to MedPage Today, and call a listed pharmacy to confirm current stock and eligibility. Those unable to find the mRNA vaccine can discuss other available flu vaccines with a healthcare professional rather than postponing vaccination while searching.
For the evidence question, the next key development is the FDA-required postmarketing effectiveness study in adults 65 and older. Its design and eventual findings could help clarify how mFlusiva performs against an enhanced vaccine. No results or study timeline were provided in the report.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who can get Moderna’s mRNA flu vaccine?
mFlusiva is approved for adults ages 50 and older. The FDA granted traditional approval for ages 50 to 64 and accelerated approval for people 65 and older, with a postmarketing effectiveness study planned for the older group.
Where can I find mFlusiva?
Moderna told MedPage Today the vaccine is available at more than 13,000 locations and shared a link to its vaccine finder. Because the launch is limited and the report does not confirm local inventory, call the pharmacy before visiting.
Does mFlusiva work better than other flu shots?
That has not been established by clinical-outcome comparisons with enhanced flu vaccines. One study found a stronger immune response than Fluzone High-Dose in adults 65 and older, but it did not measure clinical protection. The FDA has called for a postmarketing effectiveness study.
Should I wait if I cannot find the mRNA shot?
Schaffner advised people who have not been vaccinated to get an available flu vaccine. If you are unsure which product is appropriate for you, ask a healthcare professional; local stock of mFlusiva may be limited.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
